Encouraging Results on Briquilimab as Conditioning Therapy for Fanconi Anemia Patients

A recent clinical trial has shown promising results for the treatment of Fanconi Anemia (FA) using a new antibody therapy named briquilimab. The biotech firm Jasper Therapeutics, Inc., which is developing this innovative treatment, has reported that all participants in the study experienced successful engraftment of donor stem cells and a full recovery in blood count, with the drug being well-tolerated.
The positive outcomes were part of the Phase 1b/2a clinical trial data, which were shared at the Stanford Medicine Center for Definitive and Curative Medicine Symposium. Briquilimab, which targets the c-Kit receptor, is being explored as a potential conditioning treatment for FA patients experiencing bone marrow failure. The study's findings indicate that the drug has a favorable safety profile and is well-tolerated by FA patients.
Edwin Tucker, the Chief Medical Officer at Jasper, expressed optimism about the drug's potential to be a significant part of non-toxic conditioning regimens for stem cell transplants. He also acknowledged the contributions of Stanford Medicine in evaluating briquilimab's effectiveness in treating this patient group.
Briquilimab is a monoclonal antibody that works by blocking the binding of stem cell factor to c-Kit, thus disrupting the survival signal for mast cells and reducing inflammation in diseases like chronic urticaria. The drug is also being studied for its use in treating lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for cell and gene therapies for rare diseases. It has demonstrated efficacy and safety in over 145 participants across various clinical studies.
Fanconi Anemia is a severe blood disorder characterized by the bone marrow's inability to produce enough red blood cells and can lead to life-threatening complications like bone marrow failure and certain cancers. The only known cure for FA is a hematopoietic stem cell transplant (HSCT). The clinical trial in question is an open-label study that investigates briquilimab as a substitute for traditional chemotherapy or irradiation in the transplant process, using a specific dosage in combination with other medications for lymphodepletion.
Jasper Therapeutics is a clinical-stage company that is advancing briquilimab as a therapeutic option for various conditions, including chronic urticaria, MDS, and as a conditioning agent for stem cell transplants for rare diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!